Anna Mäkinen1, Taina Härkönen, Jorma Ilonen, Mikael Knip. 1. Scientific Laboratory, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Biomedicum I, PO Box 63, FI-00014 Helsinki, Finland.
Abstract
OBJECTIVE: To characterize the humoral immune response to islet antigen 2 (IA-2) in patients with newly diagnosed type 1 diabetes (T1D), we compared the profile of epitope- and isotype-specific IA-2 antibodies (IA-2A) between children with a humoral immune response restricted to IA-2 and children with a broad response including insulin autoantibodies (IAA) and antibodies to glutamic acid decarboxylase (GADA) in addition to IA-2A. METHODS: The study subjects (n=100) were derived from a consecutive series of 1108 patients from the Finnish Pediatric Diabetes Register (investigators listed in the Appendix). Islet cell antibodies, IAA, GADA, total IA-2A levels, IA-2/IA-2beta epitopes, and isotypes were measured, and human leukocyte antigen (HLA) genotypes were analyzed. RESULTS: There were no significant differences between the two groups in the frequency or levels of epitope-specific IA-2A. Those with an IA-2-restrictive response tested positive more frequently for IgA-IA-2A (P=0.001), had higher titers of IgE-IA-2A (P=0.025), tested positive for more IA-2A isotypes than the broad responders (P=0.04), and carried the high-risk HLA-(DR4)-DQB1*0302 haplotype more frequently than those with a broad antibody response (P=0.019). CONCLUSIONS: These data show that children with newly diagnosed T1D, who test positive only for IA-2A out of the three molecular antibodies predictive of T1D, have a broader IA-2-specific isotype response and stronger association with the high-risk HLA haplotype than those testing positive for all three molecular antibodies. This may be indicative of a different pathogenetic mechanism in those with their humoral immune response restricted to IA-2 at the time of diagnosis.
OBJECTIVE: To characterize the humoral immune response to islet antigen 2 (IA-2) in patients with newly diagnosed type 1 diabetes (T1D), we compared the profile of epitope- and isotype-specific IA-2 antibodies (IA-2A) between children with a humoral immune response restricted to IA-2 and children with a broad response including insulin autoantibodies (IAA) and antibodies to glutamic acid decarboxylase (GADA) in addition to IA-2A. METHODS: The study subjects (n=100) were derived from a consecutive series of 1108 patients from the Finnish Pediatric Diabetes Register (investigators listed in the Appendix). Islet cell antibodies, IAA, GADA, total IA-2A levels, IA-2/IA-2beta epitopes, and isotypes were measured, and human leukocyte antigen (HLA) genotypes were analyzed. RESULTS: There were no significant differences between the two groups in the frequency or levels of epitope-specific IA-2A. Those with an IA-2-restrictive response tested positive more frequently for IgA-IA-2A (P=0.001), had higher titers of IgE-IA-2A (P=0.025), tested positive for more IA-2A isotypes than the broad responders (P=0.04), and carried the high-risk HLA-(DR4)-DQB1*0302 haplotype more frequently than those with a broad antibody response (P=0.019). CONCLUSIONS: These data show that children with newly diagnosed T1D, who test positive only for IA-2A out of the three molecular antibodies predictive of T1D, have a broader IA-2-specific isotype response and stronger association with the high-risk HLA haplotype than those testing positive for all three molecular antibodies. This may be indicative of a different pathogenetic mechanism in those with their humoral immune response restricted to IA-2 at the time of diagnosis.
Authors: Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio Journal: Diabetologia Date: 2015-02-10 Impact factor: 10.122
Authors: Jorma Ilonen; Anna Hammais; Antti-Pekka Laine; Johanna Lempainen; Outi Vaarala; Riitta Veijola; Olli Simell; Mikael Knip Journal: Diabetes Date: 2013-07-08 Impact factor: 9.461
Authors: Jordan T Russell; Luiz F W Roesch; Malin Ördberg; Jorma Ilonen; Mark A Atkinson; Desmond A Schatz; Eric W Triplett; Johnny Ludvigsson Journal: Nat Commun Date: 2019-08-09 Impact factor: 14.919
Authors: Heli T A Siljander; Satu Simell; Anne Hekkala; Jyrki Lähde; Tuula Simell; Paula Vähäsalo; Riitta Veijola; Jorma Ilonen; Olli Simell; Mikael Knip Journal: Diabetes Date: 2009-09-15 Impact factor: 9.461
Authors: L Yeo; I Pujol-Autonell; R Baptista; M Eichmann; D Kronenberg-Versteeg; S Heck; G Dolton; A K Sewell; T Härkönen; M-L Mikk; J Toppari; R Veijola; M Knip; J Ilonen; M Peakman Journal: Clin Exp Immunol Date: 2019-11-10 Impact factor: 4.330